Urovant Sciences Ltd (NASDAQ:UROV) major shareholder Holdings Ltd. Dexxon purchased 11,608 shares of the business’s stock in a transaction on Friday, May 17th. The stock was acquired at an average price of $7.10 per share, with a total value of $82,416.80. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Shares of NASDAQ UROV opened at $8.33 on Wednesday. Urovant Sciences Ltd has a 52-week low of $4.05 and a 52-week high of $14.49.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. FMR LLC grew its stake in shares of Urovant Sciences by 28.4% during the 1st quarter. FMR LLC now owns 1,710,836 shares of the company’s stock valued at $17,194,000 after buying an additional 378,135 shares during the period. Perceptive Advisors LLC boosted its position in Urovant Sciences by 38.4% during the 1st quarter. Perceptive Advisors LLC now owns 865,359 shares of the company’s stock worth $8,697,000 after purchasing an additional 240,000 shares during the period. BlackRock Inc. purchased a new stake in Urovant Sciences during the 3rd quarter worth $4,574,000. Sphera Funds Management LTD. boosted its position in Urovant Sciences by 30.5% during the 4th quarter. Sphera Funds Management LTD. now owns 214,030 shares of the company’s stock worth $1,410,000 after purchasing an additional 50,000 shares during the period. Finally, Prosight Management LP purchased a new stake in Urovant Sciences during the 1st quarter worth $1,004,000. 22.77% of the stock is owned by institutional investors.
About Urovant Sciences
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.
Recommended Story: Quick Ratio
Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.